Protective and therapeutic use of digestion resistant starch (MSPrebiotic®) in a pig model of experimental colitis

新兴的治疗药物被用于减轻肠道炎症和微生物失调，包括饮食供应的益生菌和益生菌。抗消化淀粉(DRS)代表了一系列不同的膳食碳水化合物旁路进入低位肠道，在那里它经历了微生物发酵。在过去的几年里，DRS通过平衡微生物区系组成和短链脂肪酸水平对肠道健康的影响进行了研究。据推测，DRS可以通过改变肠道微生物区系、可能调节局部炎性细胞因子及其对粘膜屏障系统的影响来减轻结肠炎症状和病理。总部位于马尼托巴省的全球生物技术公司MS PreBiotic Inc.开发了一种广受欢迎的马铃薯DR产品，名为MSPreBiotic®。该公司正在寻求一个项目，以优化他们对MS PreBiotic®的建议，将其作为减少肠道炎症和改善肠道健康的预防和/或治疗工具。在此，我们研究了DRS(MSPreBiotic®)在猪实验性结肠炎模型中的保护和治疗效果。猪将接受5种不同的处理，包括1)基础对照日粮，2)结肠炎日粮(1%卡拉胶)，3)DRS日粮，4)结肠炎日粮2周，然后引入DRS日粮(以衡量DRS的疗效)，5)DRS日粮2周，然后是结肠炎日粮(以衡量DRS的保护效果)。粪便浓度和大肠组织学将被用作胃肠道炎症的衡量标准。将对血液样本进行全身炎症标志物分析。将使用内部16S rRNA基因测序来评估Gut微生物区系概况，然后使用PICRUST预测微生物群落的功能能力。这项研究的结果将帮助该公司优化他们的建议，将MSPreBiotic®作为一种预防和/或治疗方法使用，以减少肠道炎症和改善肠道健康。

Emerging therapeutics are used to alleviate intestinal inflammation and microbial dysbiosis including dietarysupplies of prebiotics and probiotics. Digestion resistant starch (DRS) represents a diverse range of dietarycarbohydrates bypassing into the lower gut where it undergoes microbial fermentation. DRS has beeninvestigated in the past years for its effects on gut health via balancing the microbiota composition and shortchain fatty acid levels. It is speculated that DRS can reduce colitis symptoms and pathology throughmodification of the gut microbiota, possible regulation of local inflammatory cytokines and its effects onmucosal barrier system.MSPrebiotic Inc., a Manitoba-based global biotechnological company, has developed a popular potato DRSproduct named MSPrebiotic®. The company is seeking a project to optimize their recommendations foradministration of MSPrebiotic® either as a preventative and/or therapeutic tool for reducing gut inflammationand improving gut health.Here, we investigate the protective and therapeutic effects of DRS (MSPrebiotic®) in a pig model ofexperimental colitis. Pigs will receive 5 different treatments including 1) basal control diet, 2) colitis-inducingdiet (1% carrageenan gum), 3) DRS diet, 4) colitis-inducing diet for 2 weeks followed by introduction of DRSdiet (to measure therapeutic effect of DRS), and 5) DRS diet for 2 weeks followed by a colitis-inducing diet (tomeasure the protective effect of DRS). Fecal consistency and large intestine histology will be used as measuresof gastrointestinal inflammation. Blood samples will be analyzed for systemic inflammatory markers. Gutmicrobiota profile will be assed using 16S rRNA gene sequencing in-house followed by prediction offunctional capacity of the microbial community using PICRUSt. The outcome of this research will help thecompany to optimize their recommendations for the use of MSPrebiotic® as a preventative and/or therapeuticapproach for reducing gut inflammation and improving gut health.